Acceleron Pharma Inc

Overview

Acceleron Pharma Inc (Acceleron) is a clinical stage biopharmaceutical company that discovers, develops and commercializes drugs to treat serious and rare diseases. Reblozyl is the company’s only commercial product used for the treatment of transfusion-dependent anemia patients with beta thalassemia and myelodysplastic syndromes (MDS). The company’s lead therapeutic candidate, luspatercept-aamt is in clinical trials for the treatment of anemia and associated complications in myelodysplastic syndromes, and myelofibrosis. Its other pipeline products are being evaluated for the treatment of lung disease. The company has operations in the US, Bermuda and Switzerland. Acceleron Pharma is headquartered in Cambridge, Massachusetts, the US.
Key Stats
Address
128 Sidney St, CAMBRIDGE, Massachusetts
Headquarters

United States of America

Contact

1 617 6499200

No of Employees

312

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

XLRN [NASD]

Revenue (2020)

$93 m

25.7% (2020 vs 2019)
Net Income (2020)

$-166 m

-33% (2020 vs 2019)
Net Profit Margin

-179 %

-6.4% (2020 vs 2019)
Market Cap *

$7,887 m

EPS *

$-2.9

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Acceleron Pharma IncNovartis AGbluebird bio IncOnconova Therapeutics Inc
Key Information
Headquarters United States of America Switzerland United States of America United States of America
Headquarter City CAMBRIDGE BASEL CAMBRIDGE NEWTOWN
Headquarter State/Province Massachusetts - Massachusetts Pennsylvania
No. of Employees 312 109,000 1,213 11
Entity Type Public Public Public Public

Products & Services

Acceleron Pharma is a drug development company. The key products offered by the company include the following:

Products
  • Commercial:
  • Reblozyl (luspatercept-aamt)- for anemia with beta-thalassemia and myelodysplastic syndromes patients.
  • Pipeline Product:
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Sujay Kango Chief Commercial Officer; Executive Vice President Senior Management 2018 57 Mr. Sujay Kango has been the Chief Commercial Officer and the Executive Vice President of the company since 2018. Prior...
Habib J. Dable Chief Executive Officer; Director; President Executive Board 2016 51 Mr. Habib J. Dable has been the President, Chief Executive Officer and Director of the company since 2016. Prior to...
Francois Nader, M.D. Chairman Executive Board 2015 64 Dr. Francois Nader has been the Chairman of the company since 2015. Prior to this, he was the President, Chief...
Kevin Mclaughlin Chief Financial Officer; Senior Vice President; Treasurer Senior Management 2010 64 Mr. Kevin McLaughlin is the Senior Vice President, Chief Financial Officer and Treasurer of the company. Prior to this, he...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Regulatory Approval In February, the company received approval for Reblozyl from Health Canada for the treatment of…
2020 Regulatory Approval In April, the company received approval for Reblozyl from the FDA for the treatment of…
2020 Regulatory Approval In April, the company received Breakthrough Therapy Designation for Sotatercept from the FDA for the…
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2020 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Acceleron Securities Corp
Acceleron Holding Ltd
Acceleron Pharma Switzerland AG

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
29 Jun 2020 Acceleron Pharma Raises USD517.5 Million in Pubic Offering of Shares Equity Offering Acceleron Pharma Inc
20 Dec 2019 Acceleron Pharma Enters into Licensing Agreement with Fulcrum Therapeutics Licensing Agreement Acceleron Pharma Inc Fulcrum Therapeutics Inc
16 Jan 2019 Acceleron Pharma Prices Public Offering of Shares for USD230 Million Equity Offering Acceleron Pharma Inc
26 Jul 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
15 Feb 2018 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
19 Sep 2017 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

49

Active Jobs

18

Posted

18

Closed

Job Trends

Latest Jobs

Job title Company Country
Scientist I, Bioanalysis and Pharmacokinetics Acceleron Pharma Inc United States
Senior Scientist, Immunology Acceleron Pharma Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar